

# **Technical Data**

# **Cetrimide Agar**

# **MH024**

# Intended use

Recommended for the selective isolation of *Pseudomonas aeruginosa* from pharmaceutical products in accordance with the microbial limit testing by harmonized methodology of USP/EP/BP/JP/IP.

# **Composition\*\***

Ingredients	Gms / Litre
Gelatin peptone #	20.000
Magnesium chloride	1.400
Dipotassium sulphate	10.000
Cetrimide	0.300
Agar	13.600
pH after sterilization (at 25°C)	7.2±0.2

\*\*Formula adjusted, standardized to suit performance parameters

# Pancreatic digest of gelatin

## **Directions**

Suspend 45.3 grams in 1000 ml purified/distilled water containing 10 ml glycerin/glycerol. Heat to boiling to dissolve the medium completely. Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes or as per validated cycle. Cool to 45-50°C. Mix well and pour into sterile Petri plates.

# **Principle And Interpretation**

Cetrimide Agar was described by King et al (1). This media formulation is in accordance with the harmonized method of USP/EP/BP/JP/IP (2-6). It is used as a selective medium for the isolation of *Pseudomonas aeruginosa* from

pharmaceutical products. This medium is also used for microbial limit testing for non- sterile products. Lowbury first reported the use of cetrimide as an agent for selective isolation of *Pseudomonas* (7). This medium is also used for determining the ability of an organism to produce fluorescein and pyocyanin. Cetrimide (N-acetyl-N,N,N-trimethylammonium bromide) is incorporated in the medium to inhibit bacteria other than *Pseudomonas aeruginosa*. This compound a cationic detergent acts as a quaternary ammonium compound, which causes nitrogen and phosphorus to be released from bacterial cells other than *Pseudomonas aeruginosa*. Magnesium chloride and potassium sulphate incorporated in the medium enhances the production of pigment pyocyanin, which is a blue-green pigment, diffusing into the medium. This improves detection of *Pseudomonas* on this medium. Presence of magnesium ions can also neutralizes EDTA, if present in the sample. Gelatin peptone provides the essential nutrients for growth of *Pseudomonas*, while glycerin serves as slow and continuous carbon source for the growing cell.

For the isolation of *Pseudomonas aeruginosa*, plates of Cetrimide Agar should be inoculated from non-selective medium such as Soybean Casein Digest Medium (MH011). If the count is high the test sample can be directly inoculated onto this medium. *Pseudomonas aeruginosa* colonies may appear pigmented greenish (under uv light also).

## **Type of specimen**

Pharmaceutical samples

# **Specimen Collection and Handling**

For pharmaceutical samples, follow appropriate techniques for sample collection, processing as per guidelines (2-6). After use, contaminated materials must be sterilized by autoclaving before discarding.

## Warning and Precautions:

Read the label before opening the container. Wear protective gloves/protective clothing/eye protection/face protection. Follow good microbiological lab practices while handling specimens and culture. Standard precautions as per established guidelines should be followed while handling specimens. Safety guidelines may be referred in individual safety data sheets.

## Limitations

1. Individual organisms differ in their growth requirement and may show variable growth patterns on the medium.

- 2. Each lot of the medium has been tested for the organisms specified on the COA. It is recommended to users to validate the medium for any specific microorganism other than mentioned in the COA based on the user's unique requirement.
- 3. This medium is a selective medium, some strains may show poor growth as cetrimide is highly toxic.
- 4. Further biochemical tests must be carried out for complete identification.

## **Performance and Evaluation**

Performance of the medium is expected when used as per the direction on the label within the expiry period when stored at recommended temperature.

#### **Quality Control**

#### Appearance

Cream to yellow homogeneous free flowing powder

Gelling

Firm, comparable with 1.36% Agar gel

#### Colour and Clarity of prepared medium

Light amber coloured opalescent gel with a slight precipitate forms in Petri plates

pН

7.00-7.40

# **Growth Promotion Test**

Growth Promotion is carried out in accordance with the harmonized method of USP/EP/BP/JP/IP. Cultural response was observed after an incubation at 30-35°C for specified time. Recovery rate is considered as 100% for bacteria growth on Soybean Casein Digest Agar.

#### Growth promoting properties

Growth of microorganism comparable to that previously obtained with previously tested and approved lot of medium occurs at the specified temperature for not more than the shortest period of time specified inoculating  $\leq 100$  cfu (at 30-35°C for  $\leq 18$  hours).

#### **Inhibitory properties**

No growth of the test microorganism occurs for the specified temp for not less than longest period of time specified inoculating  $\geq 100$  cfu (at least 100 cfu) (at 30-35°C for  $\geq 72$  hours).

#### **Cultural Response**

Cultural characteristics observed after incubation at 30-35 °C for 18-72 hours. Recovery rate is considered as 100% for bacteria growth on Soyabean Casein Digest Agar.

Organism	Inoculum (CFU)	Growth	Observed Lot value (CFU)	Recovery	Incubation temperature	Incubation period		
Growth promoting								
Pseudomonas aeruginosa ATCC 9027 (00026*)	50 -100	luxuriant	25 -100	>=50 %	30 -35 °C	<=18 hrs		
Inhibitory								
<i>Escherichia coli ATCC 873</i> (00012*)	9>=10 <sup>3</sup>	inhibited	0	0 %	30 -35 °C	>=72 hrs		
Additional Microbiological								
testing								
Pseudomonas aeruginosa ATCC 27853(00025*)	50 -100	luxuriant	25 -100	>=50 %	30 -35 °C	18 -24 hrs		
Pseudomonas aeruginosa ATCC 25668 (00114*)	50 -100	luxuriant	25 -100	>=50 %	30 -35 °C	18 -24 hrs		
Stenotrophomonas maltophila ATCC 13637	>=10 <sup>3</sup>	inhibited	0	0%	30 -35 °C	>=72 hrs		
Escherichia coli ATCC 25922 (00013*)	>=10 <sup>3</sup>	inhibited	0	0%	30 -35 °C	>=72 hrs		
Escherichia coli NCTC 900	$02 >= 10^3$	inhibited	0	0%	30 -35 °C	>=72 hrs		
Staphylococcus aureus	>=10 <sup>3</sup>	inhibited	0	0%	30 -35 °C	>=72 hrs		
subsp. aureus ATCC 6538 (00032*) Staphylococcus aureus subsp. aureus ATCC 25923 (00034*)	>=10 <sup>3</sup>	inhibited	0	0%	30 -35 °C	>=72 hrs		
Salmonella Typhimurium	>=10 <sup>3</sup>	inhibited	0	0%	30 -35 °C	>=72 hrs		
ATCC 14028 (00031*) Proteus mirabilis ATCC	>=10 <sup>3</sup>	inhibited	0	0%	30 -35 °C	>=72 hrs		
29906 (00023*) Key : (*) Corresponding WDCM numbers.								

Please refer disclaimer Overleaf.

#### **Storage and Shelf Life**

Store between 10-30°C in a tightly closed container and the prepared medium at 20-30°C. Use before expiry date on the label. On opening, product should be properly stored dry, after tightly capping the bottle in order to prevent lump formation due to the hygroscopic nature of the product. Improper storage of the product may lead to lump formation. Store in dry ventilated area protected from extremes of temperature and sources of ignition Seal the container tightly after use. Product performance is best if used within stated expiry period.

#### Disposal

User must ensure safe disposal by autoclaving and/or incineration of used or unusable preparations of this product. Follow established laboratory procedures in disposing of infectious materials and material that comes into contact with sample must be decontaminated and disposed of in accordance with current laboratory techniques (4,8).

#### Reference

1.King, Ward and Raney, 1954, J. Lab. Clin. Med., 44:301.

2.British Pharmacopoeia, 2022, The Stationery office British Pharmacopoeia

3. European Pharmacopoeia, 2022 European Dept. for the quality of Medicines.

4.Indian Pharmacopoeia, 2020, Govt. of India, Ministry of Health and Family Welfare, New Delhi

5. Japanese Pharmacopoeia, 2016

6. The United States Pharmacopoeia, 2022, The United States Pharmacopeial Convention. Rockville, MD.

7.Lowbury E J L., 1951, J.Clin.Path., 4:66.

8. Isenberg, H.D. Clinical Microbiology Procedures Handbook. 2nd Edition

9.Jorgensen, J.H., Pfaller, M.A., Carroll, K.C., Funke, G., Landry, M.L., Richter, S.S and Warnock., D.W., 11th Ed., 2015, Manual of Clinical Microbiology.

Revision : 05/ 2022

#### Disclaimer :

User must ensure suitability of the product(s) in their application prior to use. Products conform solely to the information contained in this and other related HiMedia<sup>™</sup> publications. The information contained in this publication is based on our research and development work and is to the best of our knowledge true and accurate. HiMedia<sup>™</sup> Laboratories Pvt Ltd reserves the right to make changes to specifications and information related to the products at any time. Products are not intended for human or animal or therapeutic use but for laboratory, diagnostic, research or further manufacturing use only, unless otherwise specified. Statements contained herein should not be considered as a warranty of any kind, expressed or implied, and no liability is accepted for infringement of any patents.